Product image of Mydriasert (Phenylephrine Hydrochloride, Tropicamide) supplied by GNH India

Mydriasert

Active Ingredient:
Phenylephrine Hydrochloride, Tropicamide
Origin:
EU

Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride and Tropicamide, the active ingredients in Mydriasert, are mydriatic agents presented as an ophthalmic solution for ocular use. The combination rapidly dilates the pupil, aiding comprehensive eye examinations and facilitating intra‑ocular surgical procedures in adult patients.

GNH India supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across global markets. Originating from the European Union, the product meets EU pharmacopeial standards throughout its lifecycle.

Manufacturer / TM Owner

Laboratoires Thea

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mydriasert, a combination mydriatic ophthalmic solution, acts on the ocular pupil muscles to produce dilation.

  • Eye examinations: provides sufficient pupil dilation for thorough retinal and optic nerve assessment.
  • Intra‑ocular procedures: facilitates surgical access by maintaining a wide pupil during cataract or laser surgery.
  • Diagnostic imaging: enables high‑quality fundus photography and optical coherence tomography.
  • Pre‑operative preparation: dilates pupils before cataract extraction to improve surgeon visibility.

How It Works

  • Phenylephrine hydrochloride is an alpha‑1 adrenergic receptor agonist that contracts the dilator pupillae muscle, while tropicamide is a muscarinic antagonist that relaxes the sphincter pupillae muscle. The concurrent activation and inhibition of these pathways produce a rapid and sustained dilation of the pupil, improving ocular exposure for examination and surgery.

Side Effects

Mydriasert may cause ocular and systemic reactions following administration.

Common Side Effects

  • Transient ocular discomfort or stinging.
  • Blurred vision lasting several hours.
  • Photophobia due to enlarged pupil.
  • Mild conjunctival redness.

Serious or Rare Side Effects

  • Acute angle‑closure glaucoma.
  • Severe allergic reaction (e.g., edema, rash, anaphylaxis).
  • Systemic hypertension or tachycardia.
  • Persistent intra‑ocular pressure elevation.
  • Ocular ischemia or corneal edema.

Precautions & Warnings

Use of Mydriasert requires careful assessment and monitoring.

  • Assess intra‑ocular pressure: measure baseline pressure before instillation.
  • Narrow‑angle glaucoma: avoid or use only under specialist supervision.
  • Hypersensitivity: discontinue if allergic signs appear.
  • Cardiovascular disease: monitor for systemic blood pressure changes.
  • Concomitant mydriatics: limit combined use to prevent excessive dilation.
  • Store at room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Mydriasert can interact with systemic and ocular agents.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis with phenylephrine.
  • Tricyclic antidepressants or sympathomimetics: may potentiate systemic vasoconstriction.
  • Anticholinergic drugs: increased ocular anticholinergic effect with tropicamide.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers or antihypertensives: possible attenuation of systemic blood pressure rise.
  • Other mydriatic agents: risk of excessive pupil dilation.
  • Topical ocular steroids: may mask signs of increased intra‑ocular pressure.

Frequently Asked Questions

Mydriasert is an ophthalmic solution containing phenylephrine hydrochloride and tropicamide that is used to induce pupil dilation (mydriasis) for eye examinations, diagnostic imaging, and intra‑ocular surgical procedures.

Phenylephrine stimulates alpha‑1 receptors in the dilator pupillae muscle, causing contraction, while tropicamide blocks muscarinic receptors in the sphincter pupillae muscle, leading to relaxation. The combined effect rapidly widens the pupil.

The dosing regimen for Mydriasert is determined by the prescribing ophthalmologist based on the specific clinical need, patient age, and ocular condition. The prescriber will specify the number of drops and timing.

Safety data for Mydriasert in pregnancy or lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Mydriasert product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mydriasert combines an alpha‑adrenergic agonist (phenylephrine) with an anticholinergic (tropicamide), offering rapid and sustained dilation. Compared with single‑agent drops such as atropine or cyclopentolate, Mydriasert often achieves quicker onset and may require fewer applications, but choice depends on the clinical scenario and physician preference.

Mydriasert should be stored at room temperature, below 25 °C, in its original container. Protect the solution from light and moisture to maintain stability.

Mydriasert is applied topically to the eye as a drop. The prescriber will instruct the patient on the number of drops per eye and the interval between applications, typically performed in a clinical setting.

Serious risks include acute angle‑closure glaucoma, severe allergic reactions, and systemic hypertension or tachycardia. Patients should be monitored for signs of increased intra‑ocular pressure, allergic symptoms, or cardiovascular changes after administration.

Mydriasert should be avoided in patients with known hypersensitivity to phenylephrine, tropicamide, or any excipients, and in individuals with narrow‑angle or uncontrolled glaucoma unless directed by an eye‑care specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Phenylephrine Hydrochloride, Tropicamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT